[1] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[2] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[3] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[4] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[5] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[6] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[7] |
CHEN Chao, ZHU Lan, LIU Lihong, HAN Jiayin, ZHU Yan.
Characteristics of Psoralea corylifolia induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 449-453.
|
[8] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[9] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[10] |
GENG Kexin, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, SA Rina, JIANG Hao, ZOU Lina.
Safety of traditional Chinese medicine among lactating women and pharmacovigilance
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 908-912.
|
[11] |
SUN Bao, BAI Yanning, ZHANG Yuanyuan, QIAO Yi, YANG Zhifu, WANG Jingwen, WEN Aidong.
Literature review of eosinophilic pneumonia induced by daptomycin
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 757-761.
|
[12] |
WANG Xiaofang, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, WEI Changce.
Pharmacovigilance and pharmaceutical care of traditional Chinese medicine based on ancient pediatric literature
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 591-594.
|
[13] |
ZHANG Ruili, SU Shuang, JIANG Jiming, ZHANG Jing.
Thirty-six cases of adverse drug reactions/events caused by Xinhuang tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 561-563.
|
[14] |
MAO Shumin, QIU Jianmin, ZHAO Xifeng, LYU Xinhua.
257 cases of adverse drug reactions induced by lidocaine hydrochloride injection used in dentistry
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 417-420.
|
[15] |
HUANG Li, WEI Long, LI Hemei, YI Dan.
Literature review of 58 cases of adverse drug reactions induced by flurbiprofen
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 436-440.
|